CHMP of the European Medicines Agency Recommends Approval of Blenrep (belantamab mafodotin) for Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/CHMP-positive-approval-blenrep-belantamab-mafodotin)